#Canada #Aurora Cannabis #Edmonton #Faris El Refaie #Global Commercial

Aurora Welcomes a New Era of Leadership

Aurora Cannabis Inc., a prominent player in the global medical cannabis landscape, has made a significant leadership change designed to propel its commercial activities on a worldwide scale. On September 28, 2026, Faris El Refaie will officially join the company as the Executive Vice President of Global Commercial. This move is expected to advance Aurora's mission of expanding access to high-quality medical cannabis products across various international markets.

Faris brings an impressive portfolio of expertise to Aurora, boasting over 25 years in the biopharmaceutical industry. His extensive background includes leadership roles in high-profile companies such as GSK, AstraZeneca, and JAMP Pharma Group, where he has honed his skills in commercial growth, product strategy, and market expansion. This experience equips him to effectively lead Aurora’s efforts in aligning its global portfolio and developing robust customer engagement practices.

A Vision for Growth

The appointment comes at a crucial time for Aurora, as it seeks to solidify its position in an increasingly competitive market. Current CEO Miguel Martin expressed excitement about Faris joining the team, emphasizing his experience in navigating complex biopharmaceutical fields, including oncology and specialty care. Martin stated, “Faris's strategic vision will undoubtedly bolster our global strategy, helping us to provide quality cannabis solutions to patients everywhere.”

In his newly established role, Faris will be tasked with overseeing Aurora’s entire global commercial operations. This includes entering new international markets while enhancing existing customer relationships across various regions, such as Canada, Europe, Australia, and New Zealand. His leadership is expected to guide Aurora in meeting its ambitious objectives of forging a stronger presence in both established and emerging markets.

Aurora’s Commitment to Excellence

Aurora Cannabis has consistently been a leader in the medical cannabis space, recognized for its commitment to quality, scientific research, and patient care. The company operates GMP-certified manufacturing facilities in Canada and Germany, ensuring that they maintain the highest standards of product quality.

With a diverse portfolio that encompasses trusted brands such as Aurora®, MedReleaf®, and Pedanios®, Aurora is positioned to expand its global reach significantly under Faris's commercial direction. By aligning its global strategies, the company aims not only to drive revenue growth but also to enhance its offerings as part of a larger commitment to improving patient outcomes.

Conclusion

As Aurora Cannabis embarks on this pivotal phase of growth, the appointment of Faris El Refaie as EVP of Global Commercial marks a significant strategic move that reflects the company's ambition to lead within the medical cannabis sector. Moving forward, all eyes will be on how this seasoned executive will mold the company's approach to international markets, customer engagement, and overall commercial success. Aurora is more than just a company; it represents a vision of opening doors for patients in need of cannabis-based therapies. As they strive to fulfill their mission of 'Opening the World to Cannabis™,' the future looks increasingly bright with Faris at the helm of their global commercial strategy.